Earnings Winners And Losers: ATRC, GB, MDT, NVRO, ELGX
This article was originally published in Clinica
Atricure (ATRC), Greatbatch (GB), Medtronic (MDT), Nevro (NVR), and Endologix (ELGX) were some of the device companies announcing their quarterly results in the last week. We looked at which reported major success, which are struggling, and which deserve more attention in the future.
You may also be interested in...
The US FDA approved fewer novel devices in 2019 than in 2018, despite a slight increase in original PMA approvals. De novo clearances were down significantly after four straight years of increases, while panel-track PMA supplements and 510(k) clearances also declined from the 2018 totals.
NANS 2020: SPR Therapeutics' Nerve Stimulation System Provides 12-Month Pain Relief After 60-Day Treatment
SPR Therapeutics said its SPRINT neurostimulation technology achieved a 63% reduction in average pain intensity in patients with chronic low back pain.
The 500-patient REPAIR MR trial will evaluate Abbott’s MitraClip mitral valve repair device in patients who would face moderate risk during open heart surgery. MitraClip is currently approved only for patients who are not surgical candidates.